What is Opus Genetics's debt-to-equity?

Opus Genetics (IRD) reported debt-to-equity of 0.1× in Q4 2025.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Opus Genetics IRD Debt-to-equity

Debt-to-equity at other companies

AbbVieABBV

46.6×+38.6×

MeiraGTx Holdings plcMGTX

27.2×+26.1×

4D Molecular TherapeuticsFDMT

0×0.0×

Opko HealthOPK

0×0.0×

Kodiak Sciences IncKOD

0.5×-0.1×

Regeneron PharmaceuticalsREGN

0.1×0.0×

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

total debt/total stockholders equity=0.1×

Based on the most recent quarter.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's debt-to-equity?: Opus Genetics (IRD) reported debt-to-equity of 0.1× in Q4 2025.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.